Use of pyridoxine-alpha-ketoglutarate (PAK) in hepatic encephalopathy

G. R. Corazza, C. Tacconi, G. Zoli

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Pyridoxine-alpha-ketoglutarate (PAK) was administered to patients with high blood ammonia levels and with clinical signs of hepatic encephalopathy (HE). Plasma concentrations of ammonia decreased and clinical symptomatology improved. The activity of PAK was greater than that of lactulose in lowering blood ammonia levels but not significantly different in its relief of neuropsychic symptoms.

Original languageEnglish
Pages (from-to)7-13
Number of pages7
JournalInternational Journal of Clinical Pharmacology Research
Volume2
Issue number4 Suppl. 1
Publication statusPublished - 1982

Fingerprint

Hepatic Encephalopathy
Ammonia
Lactulose
conductase

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Use of pyridoxine-alpha-ketoglutarate (PAK) in hepatic encephalopathy. / Corazza, G. R.; Tacconi, C.; Zoli, G.

In: International Journal of Clinical Pharmacology Research, Vol. 2, No. 4 Suppl. 1, 1982, p. 7-13.

Research output: Contribution to journalArticle

@article{a093bfc8741c4a2a9121f3b89c39c78f,
title = "Use of pyridoxine-alpha-ketoglutarate (PAK) in hepatic encephalopathy",
abstract = "Pyridoxine-alpha-ketoglutarate (PAK) was administered to patients with high blood ammonia levels and with clinical signs of hepatic encephalopathy (HE). Plasma concentrations of ammonia decreased and clinical symptomatology improved. The activity of PAK was greater than that of lactulose in lowering blood ammonia levels but not significantly different in its relief of neuropsychic symptoms.",
author = "Corazza, {G. R.} and C. Tacconi and G. Zoli",
year = "1982",
language = "English",
volume = "2",
pages = "7--13",
journal = "International Journal of Clinical Pharmacology Research",
issn = "0251-1649",
publisher = "Bioscience Ediprint Inc.",
number = "4 Suppl. 1",

}

TY - JOUR

T1 - Use of pyridoxine-alpha-ketoglutarate (PAK) in hepatic encephalopathy

AU - Corazza, G. R.

AU - Tacconi, C.

AU - Zoli, G.

PY - 1982

Y1 - 1982

N2 - Pyridoxine-alpha-ketoglutarate (PAK) was administered to patients with high blood ammonia levels and with clinical signs of hepatic encephalopathy (HE). Plasma concentrations of ammonia decreased and clinical symptomatology improved. The activity of PAK was greater than that of lactulose in lowering blood ammonia levels but not significantly different in its relief of neuropsychic symptoms.

AB - Pyridoxine-alpha-ketoglutarate (PAK) was administered to patients with high blood ammonia levels and with clinical signs of hepatic encephalopathy (HE). Plasma concentrations of ammonia decreased and clinical symptomatology improved. The activity of PAK was greater than that of lactulose in lowering blood ammonia levels but not significantly different in its relief of neuropsychic symptoms.

UR - http://www.scopus.com/inward/record.url?scp=0020264052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020264052&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0020264052

VL - 2

SP - 7

EP - 13

JO - International Journal of Clinical Pharmacology Research

JF - International Journal of Clinical Pharmacology Research

SN - 0251-1649

IS - 4 Suppl. 1

ER -